APA

Krüger K., Burmester G. R., Wassenberg S. & Thomas M. H. (2020). Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany. : Rheumatology and therapy.

Chicago

Krüger Klaus, Burmester Gerd Rüdiger, Wassenberg Siegfried and Thomas Matthias H. 2020. Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany. : Rheumatology and therapy.

Harvard

Krüger K., Burmester G. R., Wassenberg S. and Thomas M. H. (2020). Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany. : Rheumatology and therapy.

MLA

Krüger Klaus, Burmester Gerd Rüdiger, Wassenberg Siegfried and Thomas Matthias H. Golimumab as the First-, Second-, or at Least Third-Line Biologic Agent in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis: Post Hoc Analysis of a Noninterventional Study in Germany. : Rheumatology and therapy. 2020.